Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma
Open Access
- 1 March 2022
- journal article
- editorial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (3) , 736-740.e6
Abstract
No abstract availableFunding Information
- Cancer Research Foundations of Radiumhemmet (174153)
- Uppsala Multidisciplinary Center for Advanced Computational Science
- Torsten Söderbergs Stiftelse
- Stiftelsen för Strategisk Forskning (RB13-0224)
- Knut och Alice Wallenbergs Stiftelse (2013-0093)
- Cancerfonden (CAN 2017-733)
This publication has 15 references indexed in Scilit:
- A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanomaCell Death & Disease, 2018
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic PotentialCell, 2018
- Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cellsCell Death & Disease, 2017
- DNA Damage and Repair Biomarkers of Immunotherapy ResponseCancer Discovery, 2017
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in MelanomaCell Reports, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012